These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23737728)

  • 21. Adenosine-to-inosine RNA editing meets cancer.
    Dominissini D; Moshitch-Moshkovitz S; Amariglio N; Rechavi G
    Carcinogenesis; 2011 Nov; 32(11):1569-77. PubMed ID: 21715563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Relevance of Noncoding Adenosine-to-Inosine RNA Editing in Multiple Human Cancers.
    Gu T; Fu AQ; Bolt MJ; White KP
    JCO Clin Cancer Inform; 2019 Jun; 3():1-8. PubMed ID: 31162949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.
    Wang Y; Xu X; Yu S; Jeong KJ; Zhou Z; Han L; Tsang YH; Li J; Chen H; Mangala LS; Yuan Y; Eterovic AK; Lu Y; Sood AK; Scott KL; Mills GB; Liang H
    Genome Res; 2017 Jul; 27(7):1112-1125. PubMed ID: 28411194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Better blocker: RNA interference dazzles research community.
    Garber K
    J Natl Cancer Inst; 2003 Apr; 95(7):500-2. PubMed ID: 12671010
    [No Abstract]   [Full Text] [Related]  

  • 25. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9.
    LaFountaine JS; Fathe K; Smyth HD
    Int J Pharm; 2015 Oct; 494(1):180-94. PubMed ID: 26278489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dual role of N6-methyladenosine modification of RNAs is involved in human cancers.
    He L; Li J; Wang X; Ying Y; Xie H; Yan H; Zheng X; Xie L
    J Cell Mol Med; 2018 Oct; 22(10):4630-4639. PubMed ID: 30039919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADARs and editing: The role of A-to-I RNA modification in cancer progression.
    Fritzell K; Xu LD; Lagergren J; Öhman M
    Semin Cell Dev Biol; 2018 Jul; 79():123-130. PubMed ID: 29146145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A-to-I RNA editing and cancer: from pathology to basic science.
    Gallo A; Galardi S
    RNA Biol; 2008; 5(3):135-9. PubMed ID: 18758244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organellar RNA editing.
    Chateigner-Boutin AL; Small I
    Wiley Interdiscip Rev RNA; 2011; 2(4):493-506. PubMed ID: 21957039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posttranscriptional recoding by RNA editing.
    Maas S
    Adv Protein Chem Struct Biol; 2012; 86():193-224. PubMed ID: 22243585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer.
    Qi L; Song Y; Chan THM; Yang H; Lin CH; Tay DJT; Hong H; Tang SJ; Tan KT; Huang XX; Lin JS; Ng VHE; Maury JJP; Tenen DG; Chen L
    Nucleic Acids Res; 2017 Oct; 45(18):10436-10451. PubMed ID: 28985428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the RNA editing potential of RNA-Seq data by ExpEdit.
    D'Antonio M; Picardi E; Castrignanò T; D'Erchia AM; Pesole G
    Methods Mol Biol; 2015; 1269():327-38. PubMed ID: 25577388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic lethality as an engine for cancer drug target discovery.
    Huang A; Garraway LA; Ashworth A; Weber B
    Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome editing: progress and challenges for medical applications.
    Carroll D
    Genome Med; 2016 Nov; 8(1):120. PubMed ID: 27846896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydrolytic nucleoside and nucleotide deamination, and genetic instability: a possible link between RNA-editing enzymes and cancer?
    Anant S; Davidson NO
    Trends Mol Med; 2003 Apr; 9(4):147-52. PubMed ID: 12727140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer.
    Okugawa Y; Toiyama Y; Shigeyasu K; Yamamoto A; Shigemori T; Yin C; Ichikawa T; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Araki T; Kusunoki M; Goel A
    J Transl Med; 2018 Dec; 16(1):366. PubMed ID: 30563560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogene suppression by small interfering RNAs.
    Heidenreich O
    Curr Pharm Biotechnol; 2004 Aug; 5(4):349-54. PubMed ID: 15320765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An RNA editing fingerprint of cancer stem cell reprogramming.
    Crews LA; Jiang Q; Zipeto MA; Lazzari E; Court AC; Ali S; Barrett CL; Frazer KA; Jamieson CH
    J Transl Med; 2015 Feb; 13():52. PubMed ID: 25889244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bioinformatic screen for novel A-I RNA editing sites reveals recoding editing in BC10.
    Clutterbuck DR; Leroy A; O'Connell MA; Semple CA
    Bioinformatics; 2005 Jun; 21(11):2590-5. PubMed ID: 15797904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The agents of natural genome editing.
    Witzany G
    J Mol Cell Biol; 2011 Jun; 3(3):181-9. PubMed ID: 21459884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.